ArticlePloS one2009
Immunogenic Burkholderia pseudomallei outer membrane proteins as potential candidate vaccine targets.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Melioidosis vaccines: a systematic review and appraisal of the potential to exploit biodefense vaccines for public health purposes.PLoS neglected tropical diseases · 2012Pooled it
- Current Melioidosis Diagnostic Landscape and Missed Opportunities in Biomarker Development.Diagnostics (Basel, Switzerland) · 2026Review
- Antibodies toMicroorganisms · 2026Article
- An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.Nature communications · 2025Article
- Evaluation of highly conserved Burkholderia pseudomallei outer membrane proteins as protective antigens against respiratory melioidosis.NPJ vaccines · 2025Article
- Molecular insights into pangenome localization and constructs design for Hemophilus influenza vaccine.Scientific reports · 2025Article
- Review
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Virulome and phylogenomic profiling of a novel Burkholderia pseudomallei strain from an Indian clinical isolate.Molecular genetics and genomics : MGG · 2024Article
- Review
- Designing mRNA- and Peptide-Based Vaccine Construct against Emerging Multidrug-ResistantMedicina (Kaunas, Lithuania) · 2022Article
- Vaccinomics to Design a Multi-Epitopes Vaccine forInternational journal of environmental research and public health · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- Predictive and Experimental Immunogenicity ofVaccines · 2021Article
- Use of RecombinantPathogens (Basel, Switzerland) · 2021Article
- Review
- Burkholderia pseudomallei OMVs derived from infection mimicking conditions elicit similar protection to a live-attenuated vaccine.NPJ vaccines · 2021Article
- Evaluation of the Whole Proteome ofFrontiers in medicine · 2021Article
- Current Advances inCells · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBurkholderia pseudomallei is the causative agent of melioidosis, a disease of significant morbidity and mortality in both human and animals in endemic areas. There is no vaccine towards the bacterium available in the market, and the efficacy of many of the bacterium's surface and secreted proteins are currently being evaluated as vaccine candidates. METHODOLOGY/PRINCIPAL
findingsWith the availability of the B. pseudomallei whole genome sequence, we undertook to identify genes encoding the known immunogenic outer membrane protein A (OmpA). Twelve OmpA domains were identified and ORFs containing these domains were fully annotated. Of the 12 ORFs, two of these OmpAs, Omp3 and Omp7, were successfully cloned, expressed as soluble protein and purified. Both proteins were recognised by antibodies in melioidosis patients' sera by Western blot analysis. Purified soluble fractions of Omp3 and Omp7 were assessed for their ability to protect BALB/c mice against B. pseudomallei infection. Mice were immunised with either Omp3 or Omp7, subsequently challenged with 1x10(6) colony forming units (cfu) of B. pseudomallei via the intraperitoneal route, and examined daily for 21 days post-challenge. This pilot study has demonstrated that whilst all control unimmunised mice died by day 9 post-challenge, two mice (out of 4) from both immunised groups survived beyond 21 days post-infection. CONCLUSIONS/SIGNIFICANCE: We have demonstrated that B. pseudomallei OmpA proteins are immunogenic in mice as well as melioidosis patients and should be further assessed as potential vaccine candidates against B. pseudomallei infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.